| scholarly article | Q13442814 |
| P50 | author | Vladimir Buchman | Q56441463 |
| Steven J Millership | Q64495855 | ||
| Owen M Peters | Q42404100 | ||
| P2093 | author name string | Natalia Ninkina | |
| Herman van der Putten | |||
| Hatem Salem | |||
| P2860 | cites work | Effects of Charcot-Marie-Tooth-linked mutations of the neurofilament light subunit on intermediate filament formation | Q24318392 |
| A new variant of Charcot-Marie-Tooth disease type 2 is probably the result of a mutation in the neurofilament-light gene | Q24538715 | ||
| Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies | Q24554351 | ||
| alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies | Q24653247 | ||
| Residual structure, backbone dynamics, and interactions within the synuclein family | Q24671058 | ||
| Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method | Q25938999 | ||
| Persyn, a member of the synuclein family, influences neurofilament network integrity | Q28512814 | ||
| Synucleins in glaucoma: implication of gamma-synuclein in glaucomatous alterations in the optic nerve | Q28580190 | ||
| Distribution of α‐ and γ‐synucleins in the adult rat brain and their modification by high‐dose cocaine treatment | Q28581427 | ||
| Formation of intermediate filament protein aggregates with disparate effects in two transgenic mouse models lacking the neurofilament light subunit | Q28586151 | ||
| Neurons Expressing the Highest Levels of γ-Synuclein Are Unaffected by Targeted Inactivation of the Gene | Q28587583 | ||
| ??? | Q64770129 | ||
| Discrete gene sets depend on POU domain transcription factor Brn3b/Brn-3.2/POU4f2 for their expression in the mouse embryonic retina | Q44770163 | ||
| Decrease of Hsp25 protein expression precedes degeneration of motoneurons in ALS-SOD1 mice | Q44971569 | ||
| Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. | Q46441823 | ||
| Progressive ganglion cell degeneration precedes neuronal loss in a mouse model of glaucoma | Q46704887 | ||
| Locomotor activity and evoked dopamine release are reduced in mice overexpressing A30P-mutated human alpha-synuclein | Q46768370 | ||
| Transgenic mice overexpressing tyrosine-to-cysteine mutant human alpha-synuclein: a progressive neurodegenerative model of diffuse Lewy body disease | Q46780013 | ||
| Retinal ganglion cells downregulate gene expression and lose their axons within the optic nerve head in a mouse glaucoma model. | Q46815689 | ||
| Sequence Determinants for Amyloid Fibrillogenesis of Human alpha-Synuclein | Q46950603 | ||
| Transgenic mice expressing mutant A53T human alpha-synuclein show neuronal dysfunction in the absence of aggregate formation. | Q48165522 | ||
| Pick's disease: alpha- and beta-synuclein-immunoreactive Pick bodies in the dentate gyrus | Q48456409 | ||
| Age-dependent cognitive decline and amygdala pathology in alpha-synuclein transgenic mice | Q48461166 | ||
| Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein | Q48581887 | ||
| Alpha- and gamma-synuclein proteins are present in cerebrospinal fluid and are increased in aged subjects with neurodegenerative and vascular changes. | Q49159052 | ||
| CHIP overexpression reduces mutant androgen receptor protein and ameliorates phenotypes of the spinal and bulbar muscular atrophy transgenic mouse model. | Q51580141 | ||
| Protective effects of heat shock protein 27 in a model of ALS occur in the early stages of disease progression. | Q51894120 | ||
| A mutation in the small heat-shock protein HSPB1 leading to distal hereditary motor neuronopathy disrupts neurofilament assembly and the axonal transport of specific cellular cargoes. | Q52567894 | ||
| Disruption of neurofilament network with aggregation of light neurofilament protein: a common pathway leading to motor neuron degeneration due to Charcot-Marie-Tooth disease-linked mutations in NFL and HSPB1. | Q52582284 | ||
| Induction of neuronal death by α-synuclein | Q58009056 | ||
| Heat shock protein 70 chaperone overexpression ameliorates phenotypes of the spinal and bulbar muscular atrophy transgenic mouse model by reducing nuclear-localized mutant androgen receptor protein | Q73174347 | ||
| Beta-synuclein inhibits formation of alpha-synuclein protofibrils: a possible therapeutic strategy against Parkinson's disease | Q73196542 | ||
| Neuropathology in mice expressing human alpha-synuclein | Q74139704 | ||
| Phenotypic analysis of neurofilament light gene mutations linked to Charcot-Marie-Tooth disease in cell culture models | Q80391817 | ||
| Accumulation of beta- and gamma-synucleins in the ubiquitin carboxyl-terminal hydrolase L1-deficient gad mouse | Q80441003 | ||
| Mouse model of multiple system atrophy alpha-synuclein expression in oligodendrocytes causes glial and neuronal degeneration | Q81589639 | ||
| Temporal profiles of neuronal degeneration, glial proliferation, and cell death in hNFL(+/+) and NFL(-/-) mice | Q81791749 | ||
| Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration | Q28587785 | ||
| Developmental loss and resistance to MPTP toxicity of dopaminergic neurones in substantia nigra pars compacta of gamma-synuclein, alpha-synuclein and double alpha/gamma-synuclein null mutant mice | Q28594631 | ||
| Persyn, a member of the synuclein family, has a distinct pattern of expression in the developing nervous system | Q28594866 | ||
| Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders | Q29614754 | ||
| Unraveling the mechanisms involved in motor neuron degeneration in ALS | Q29619073 | ||
| Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice | Q30476254 | ||
| Development of a new treatment for Alzheimer's disease and Parkinson's disease using anti-aggregatory beta-synuclein-derived peptides | Q30845414 | ||
| Modulation of alpha-synuclein expression in transgenic animals for modelling synucleinopathies--is the juice worth the squeeze? | Q33392127 | ||
| Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. | Q33857802 | ||
| Further evidence that neurofilament light chain gene mutations can cause Charcot-Marie-Tooth disease type 2E. | Q33935585 | ||
| beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease | Q33947152 | ||
| Altered expression of the synuclein family mRNA in Lewy body and Alzheimer's disease | Q34093055 | ||
| beta-Synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor | Q34099593 | ||
| Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of alpha-synuclein assembly by beta- and gamma-synucleins | Q34111411 | ||
| Beta-synuclein displays an antiapoptotic p53-dependent phenotype and protects neurons from 6-hydroxydopamine-induced caspase 3 activation: cross-talk with alpha-synuclein and implication for Parkinson's disease | Q34214842 | ||
| Mutant small heat-shock protein 27 causes axonal Charcot-Marie-Tooth disease and distal hereditary motor neuropathy | Q34318026 | ||
| Beta-synuclein modulates alpha-synuclein neurotoxicity by reducing alpha-synuclein protein expression | Q34564479 | ||
| Neuronal intermediate filaments and ALS: a new look at an old question | Q34574411 | ||
| Part II: alpha-synuclein and its molecular pathophysiological role in neurodegenerative disease. | Q35157623 | ||
| Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease | Q35166364 | ||
| Functions of intermediate filaments in neuronal development and disease | Q35575907 | ||
| Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation | Q35700288 | ||
| Neurodegeneration with brain iron accumulation, type 1 is characterized by alpha-, beta-, and gamma-synuclein neuropathology | Q35745646 | ||
| Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model | Q35747138 | ||
| Ubiquitination of alpha-synuclein is not required for formation of pathological inclusions in alpha-synucleinopathies | Q35791524 | ||
| Cell systems and the toxic mechanism(s) of alpha-synuclein | Q36440972 | ||
| Transgenic mouse models of amyotrophic lateral sclerosis | Q36468459 | ||
| Mechanisms and models of alpha-synuclein-related neurodegeneration. | Q36575028 | ||
| Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein | Q36677512 | ||
| In vivo alpha-synuclein overexpression in rodents: a useful model of Parkinson's disease? | Q36976137 | ||
| Hsp70 Reduces alpha-Synuclein Aggregation and Toxicity | Q40573441 | ||
| Up-regulation of protein chaperones preserves viability of cells expressing toxic Cu/Zn-superoxide dismutase mutants associated with amyotrophic lateral sclerosis | Q40975834 | ||
| Parkinson's disease-associated alpha-synuclein is more fibrillogenic than beta- and gamma-synuclein and cannot cross-seed its homologs | Q41755571 | ||
| Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters | Q42523541 | ||
| An antiaggregation gene therapy strategy for Lewy body disease utilizing beta-synuclein lentivirus in a transgenic model | Q43865449 | ||
| Motor dysfunction and gliosis with preserved dopaminergic markers in human alpha-synuclein A30P transgenic mice | Q44260175 | ||
| P433 | issue | 10 | |
| P921 | main subject | neurodegeneration | Q1755122 |
| overexpression | Q61643320 | ||
| P304 | page(s) | 1779-1794 | |
| P577 | publication date | 2009-02-26 | |
| P1433 | published in | Human Molecular Genetics | Q2720965 |
| P1476 | title | Gamma-synucleinopathy: neurodegeneration associated with overexpression of the mouse protein | |
| P478 | volume | 18 |
| Q30498862 | A β-synuclein mutation linked to dementia produces neurodegeneration when expressed in mouse brain |
| Q26777109 | Adult Astrogenesis and the Etiology of Cortical Neurodegeneration |
| Q41653656 | Alpha-, Beta-, and Gamma-synuclein Quantification in Cerebrospinal Fluid by Multiple Reaction Monitoring Reveals Increased Concentrations in Alzheimer's and Creutzfeldt-Jakob Disease but No Alteration in Synucleinopathies |
| Q34990005 | Alterations in energy metabolism, neuroprotection and visual signal transduction in the retina of Parkinsonian, MPTP-treated monkeys |
| Q90731164 | Alterations in the nigrostriatal system following conditional inactivation of α-synuclein in neurons of adult and aging mice |
| Q34173547 | Altered gene expression profiles in the hippocampus and prefrontal cortex of type 2 diabetic rats |
| Q39117185 | An exome study of Parkinson's disease in Sardinia, a Mediterranean genetic isolate |
| Q36504239 | Association of alpha-, beta-, and gamma-Synuclein with diffuse lewy body disease |
| Q35094391 | Bridging molecular genetics and biomarkers in lewy body and related disorders |
| Q34989307 | Cell-specific post-transcriptional regulation of γ-synuclein gene by micro-RNAs |
| Q44738578 | Characterization of three synuclein genes in Xenopus laevis. |
| Q35066217 | Compromised paraspeckle formation as a pathogenic factor in FUSopathies |
| Q36492845 | Contrasting effects of α-synuclein and γ-synuclein on the phenotype of cysteine string protein α (CSPα) null mutant mice suggest distinct function of these proteins in neuronal synapses. |
| Q37598290 | Defining the oligomerization state of γ-synuclein in solution and in cells |
| Q51049958 | Detection of autoantibodies to potentially amyloidogenic protein, gamma-synuclein, in the serum of patients with amyotrophic lateral sclerosis and cerebral circulatory disorders. |
| Q38093166 | Different anti-aggregation and pro-degradative functions of the members of the mammalian sHSP family in neurological disorders. |
| Q34721951 | Differential involvement of the gamma-synuclein in cognitive abilities on the model of knockout mice |
| Q38624671 | Dimebon does not ameliorate pathological changes caused by expression of truncated (1-120) human alpha-synuclein in dopaminergic neurons of transgenic mice. |
| Q35957568 | Dimebon slows progression of proteinopathy in γ-synuclein transgenic mice |
| Q27334411 | Early lethality and neuronal proteinopathy in mice expressing cytoplasm-targeted FUS that lacks the RNA recognition motif. |
| Q47095442 | Effects of neuroactive agents on axonal growth and pathfinding of retinal ganglion cells generated from human stem cells |
| Q39513366 | FUS gene mutations associated with familiar forms of amyotrophic lateral sclerosis affect cellular localization and aggregation properties of the encoded protein |
| Q35159808 | Functional alterations to the nigrostriatal system in mice lacking all three members of the synuclein family |
| Q37132099 | Fused in sarcoma (FUS) protein lacking nuclear localization signal (NLS) and major RNA binding motifs triggers proteinopathy and severe motor phenotype in transgenic mice |
| Q48678407 | Gamma-synuclein binds synaptic vesicles but does not interact with SNARE-complex proteins |
| Q34994452 | Gamma-synuclein pathology in amyotrophic lateral sclerosis |
| Q36190957 | Generation of mouse lines with conditionally or constitutively inactivated Snca gene and Rosa26-stop-lacZ reporter located in cis on the mouse chromosome 6. |
| Q30620032 | Generation of retinal ganglion cells with functional axons from human induced pluripotent stem cells |
| Q94464972 | Hydrogen Sulfide and β-Synuclein Are Involved and Interlinked in the Aging Glaucomatous Retina |
| Q35000764 | Identification of the sites of tau hyperphosphorylation and activation of tau kinases in synucleinopathies and Alzheimer's diseases |
| Q36485151 | Increased lipolysis and altered lipid homeostasis protect γ-synuclein-null mutant mice from diet-induced obesity |
| Q90211090 | Low Level of Expression of C-Terminally Truncated Human FUS Causes Extensive Changes in the Spinal Cord Transcriptome of Asymptomatic Transgenic Mice |
| Q30497967 | Myelination transition zone astrocytes are constitutively phagocytic and have synuclein dependent reactivity in glaucoma. |
| Q35884977 | Neuroinflammation in Parkinson's Disease and Related Disorders: A Lesson from Genetically Manipulated Mouse Models of α-Synucleinopathies |
| Q37587795 | Neurotoxic conversion of beta-synuclein: a novel approach to generate a transgenic mouse model of synucleinopathies? |
| Q42062219 | New α- and γ-synuclein immunopathological lesions in human brain |
| Q38540347 | Novel Sites of Neuroprotective Action of Dimebon (Latrepirdine). |
| Q35692589 | Parkinson's disease induced pluripotent stem cells with triplication of the α-synuclein locus |
| Q50996852 | Peripherally applied synthetic peptide isoAsp7-Aβ(1-42) triggers cerebral β-amyloidosis. |
| Q57721645 | Phosphorylation of the Amyloid-Beta Peptide Inhibits Zinc-Dependent Aggregation, Prevents Na,K-ATPase Inhibition, and Reduces Cerebral Plaque Deposition |
| Q28273075 | Reducing synuclein accumulation improves neuronal survival after spinal cord injury |
| Q28083418 | Role of α- and β-Synucleins in the Axonal Pathology of Parkinson's Disease and Related Synucleinopathies |
| Q34323256 | Selective pattern of motor system damage in gamma-synuclein transgenic mice mirrors the respective pathology in amyotrophic lateral sclerosis |
| Q58612205 | Suppression, Disaggregation, and Modulation of γ-Synuclein Fibrillation Pathway by Green Tea Polyphenol EGCG |
| Q38059684 | Synucleins: are they two-edged swords? |
| Q27694711 | The Synaptic Function of α-Synuclein |
| Q38139561 | The function of α-synuclein |
| Q42773836 | Transcriptomic analyses of genes and tissues in inherited sensory neuropathies. |
| Q35111136 | γ-Synuclein antibodies have neuroprotective potential on neuroretinal cells via proteins of the mitochondrial apoptosis pathway |
Search more.